Roche: licensing agreement with Blueprint Medicines
(CercleFinance.com) - On Tuesday Roche announced that it has signed a license and collaboration agreement with Blueprint Medicines of the United States for the development and marketing of new cancer treatments.
Under the terms of the agreement, Genentech, Roche's US subsidiary, will have the right to co-market pralsetinib, Blueprint's investigational treatment for lung cancer, medullary thyroid cancer and other types of thyroid cancer, on the US market.
Meanwhile, Roche will be responsible for the distribution of the drug outside the US, excluding China.
The Swiss pharmaceutical giant and Blueprint Medicines also say they want to develop the molecule in other fields of application.
Under the partnership, Blueprint will receive an upfront cash payment of 675 million dollars from Roche, which will also make a 100 million dollar investment in the company's capital.
Ultimately, Blueprint could receive up to 927 million dollars in milestone payments and royalties under the agreement.
Copyright (c) 2020 CercleFinance.com. All rights reserved.